High EGFR expression in the most common cancers, made EGFR family a tenable target for a number of monoclonal antibodies, aiming to block EGFR binding sites on the extracellular domain of the receptor or to prevent dimerization leading to the inhibition of intracellular tyrosine kinase activity and preventing the growth of EGFR-expressing tumours (Figure 5A). This evidence concerns the gene EGFR and neoplasm.